TYAN Showcases HPC, AI and Storage Server Platforms Featuring 2nd Gen Intel® Xeon® Scalable Processors at SC19
19.11.2019 17:00:00 EET | Business Wire | Press release
TYAN®, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, exhibits a broad selection of HPC, AI, storage and cloud server platforms that are optimized for enterprise and data center markets at SC19 through November 21st, Booth # 1601 in Denver’s Colorado Convention Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005008/en/
TYAN HPC Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors for Enterprises and Data Centers (Photo: Business Wire)
“Data is the foundation of the new economy, and how organizations effectively move, store and process will help determine their level of success,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “By leveraging the 2nd gen Intel® Xeon® Scalable processors, TYAN’s leading portfolio of HPC, storage and cloud server platforms enable to help our customers accelerate innovation, drive business value, and bring products and services to market faster.”
TYAN HPC and Storage Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors
TYAN’s HPC server platforms are built on the 2nd gen Intel Xeon Scalable processors with the addition of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable to deliver higher performance for a range of HPC and AI applications. The new Thunder HX FT83-B7119 features high CPU-to-GPU bandwidth for various parallel workloads. The 4U system supports 10 double-width PCIe x16 slots for GPU deployment, a single-wide x16 networking card, up to 3TB of system RAM, and its front-loading 24 hot-swap, tool-less 3.5” drive bays enable easy access with simple, tool-free installation.
More HPC platforms on display include, Thunder HX FT77D-B7109 in a 4U two-socket design with integrated Intel® Omni-Path100 gigabit networking fabric for massively parallel workloads such as scientific computing and large-scale facial recognition; Thunder HX FT48T-B7105 in a 4U pedestal workstation design delivering maximum I/O to professional power users for 3D rendering and image processing; Thunder HX GA88-B5631 with high density and performance in a 1U single-socket chassis supporting 12 DIMM slots and 5 PCIe x16 slots for machine learning and artificial intelligence applications.
Powered by 2nd gen Intel Xeon Scalable processors, TYAN storage platforms offer a variety of tiered storage implementation scenarios for data centers and enterprises across a range of Thunder SX FA100-B7118, a 4U 100-bay high-capacity cold storage, Thunder SX TN76-B7102, a 2U server storage with 24 DDR4 DIMM slots and twelve 3.5” hot-swap drive bays for data virtualization and in-memory databases, and the Thunder SX GT62H-B7106, a 1U high-performance all-flash storage with 10 U.2 NVMe drive bays for extremely high speed data streaming applications.
The new Thunder SX GT90-B7113 is a 1U dual-socket high-density storage platform supporting twelve 3.5” hot-swap SATA drives (SAS drives are supported by configuration). mounted to a service drawer and four 2.5” hot-swap NVMe U.2 drive bays in a 35” chassis depth. The platform is designed for CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
TYAN also showcases entry server platforms highlighting Intel® Xeon® E-2200 processors to offer professional-grade performance. The Thunder CX GT24E-B5556 is a 1U server optimized for cost-effective cloud gaming applications with support for up to 4 DDR4 DIMM slots, 1 double-width GPU card, and dual 10GBase-T Ethernet ports; the Thunder CX GX38-B5550 is a 1U compact sever with sub-400mm deep chassis and support for two 3.5" internal SATA drive bays for edge computing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005008/en/
Contact information
MiTAC Computing Technology Corporation/ TYAN Business Unit
Fenny Chen
fenny.chen@tyan.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom